Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vinblastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinblastine SCHEMBL3628 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL18593671 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL3629 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL14107274 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL6146 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL153952 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL19884331 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22450052 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL22022258 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB | |
| Vinblastine SCHEMBL15745871 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ATUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087297-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232113-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | TUBB4A 56/4885TUBB 32/4885TUBA3C 105/4885 |
| US-10556895-B2 | Quaternary amine compounds and antibody-drug conjugates thereof | H1-5, H1-4, CD47 | TUBB4A 56/4885TUBB 32/4885TUBA3C 105/4885 |
| US-20200087297-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | H1-5, H1-4, CD47 | TUBB4A 56/4885TUBB 32/4885TUBA3C 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.